Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 9Myeloproliferative Disorders 4Myelodysplastic Syndromes 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Monocytic, Acute 1

Interventions

Azacitidine 26venetoclax 20Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 13Biopsy 13fludarabine 12Specimen Handling 12Tacrolimus 11Mycophenolic Acid 11Decitabine 10Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 9Injections 8Cytarabine 8Busulfan 8decitabine and cedazuridine drug combination 7Melphalan 7X-Rays 5Hematopoietic Stem Cell Transplantation 5Cyclosporine 5Sirolimus 4ruxolitinib 3olutasidenib 3enasidenib 3cedazuridine 3Magnetic Resonance Spectroscopy 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Liposomes × 1 year × Clear all
NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡